CoChat

Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy

Open access
Haurigot, Virginia, Marcó, Sara, Ribera, Albert, Garcia, Miguel, Ruzo, Albert, Villacampa, Pilar, Ayuso, Eduard, Añor, Sònia, Andaluz, Anna, Pineda, Mercedes, García-Fructuoso, Gemma, Molas, Maria, Maggioni, Luca, Muñoz, Sergio, Motas, Sandra, Ruberte, Jesús, Mingozzi, Federico, Pumarola, Martí, Bosch, Fatima · 2013 · Journal of Clinical Investigation

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Abstract

For most lysosomal storage diseases (LSDs) affecting the CNS, there is currently no cure. The BBB, which limits the bioavailability of drugs administered systemically, and the short half-life of lysosomal enzymes, hamper the development of effective therapies. Mucopolysaccharidosis type IIIA (MPS IIIA) is an autosomic recessive LSD caused by a deficiency in sulfamidase, a sulfatase involved in the stepwise degradation of glycosaminoglycan (GAG) heparan sulfate. Here, we demonstrate that intracerebrospinal fluid (intra-CSF) administration of serotype 9 adenoassociated viral vectors (AAV9s) encoding sulfamidase corrects both CNS and somatic pathology in MPS IIIA mice. Following vector administration, enzymatic activity increased throughout the brain and in serum, leading to whole body correction of GAG accumulation and lysosomal pathology, normalization of behavioral deficits, and prolonged survival. To test this strategy in a larger animal, we treated beagle dogs using intracisternal or intracerebroventricular delivery. Administration of sulfamidase-encoding AAV9 resulted in transgenic expression throughout the CNS and liver and increased sulfamidase activity in CSF. High-titer serum antibodies against AAV9 only partially blocked CSF-mediated gene transfer to the brains of dogs. Consistently, anti-AAV antibody titers were lower in CSF than in serum collected from healthy and MPS IIIA-affected children. These results support the clinical translation of this approach for the treatment of MPS IIIA and other LSDs with CNS involvement.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci66778

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Research works printed but not linked: 1

  1. Hemsley, 2009, Int J Clin Pharmacol Ther., 47, S118

Cited by

See all 223

Metadata

Authors
Haurigot, V., Marcó, S., Ribera, A., Garcia, M., Ruzo, A., Villacampa, P., Ayuso, E., Añor, S., Andaluz, A., Pineda, M., García-Fructuoso, G., Molas, M., Maggioni, L., Muñoz, S., Motas, S., Ruberte, J., Mingozzi, F., Pumarola, M., & Bosch, F.
Affiliations
  • Universitat Autònoma de Barcelona (ES)
  • Children's Hospital of Philadelphia (US)
Venue
Journal of Clinical Investigation
Published
2013-07-01
Volume
123
Issue
8
Pages
3254-3271
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2085717798
Cited by
215
References
69
Citations by year
2026: 1 · 2025: 7 · 2024: 27 · 2023: 9 · 2022: 15 · 2021: 16 · 2020: 17 · 2019: 13 · 2018: 27 · 2017: 16 · 2016: 17 · 2015: 17 · 2014: 28 · 2013: 5
FWCI
15.51
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
  • Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
Funders
  • Fundación Ramón Areces
  • Generalitat de Catalunya
  • Ministerio de Ciencia e Innovación
  • MPS España
  • Universitat Autònoma de Barcelona
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
mucopolysaccharidosis type IIIA, lysosomal storage disease, AAV9, blood-brain barrier, heparan sulfate, glycosaminoglycan accumulation, intracerebroventricular administration, beagle dogs, mouse model

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. https://app.cochat.ai/papers/10.1172/jci66778
The paper
Haurigot, V., Marcó, S., Ribera, A., Garcia, M., Ruzo, A., Villacampa, P., Ayuso, E., Añor, S., Andaluz, A., Pineda, M., García-Fructuoso, G., Molas, M., Maggioni, L., Muñoz, S., Motas, S., Ruberte, J., Mingozzi, F., Pumarola, M., & Bosch, F. (2013). Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. Journal of Clinical Investigation. https://doi.org/10.1172/jci66778

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.